Anondita Medicare LtdNSE:ANONDITA
Current view Q4 2026
Makes low-cost latex condoms; profit doubled to ~27cr and capacity nearly doubled, with a first 43cr South Africa export order shipping - but the stock trades at 78x earnings and profit isn't turning into cash.
Latest exchange filings last 5 · 5 after Q4 2026
- 11 Sep ’26Book closure September 22-29, 2026 for 3rd AGM; remote e-voting cut-off September 22, 2026. ↗
- 9 Sep ’26September 9, 2026 newspaper ads published for odd-lot disposal arrangements under the Rights Issue. ↗
- 8 Sep ’26Partial withdrawal of corrigendum to rights issue; original 9,58,000 shares and ₹9,101 lakh issue size remain. ↗
- 7 Sep ’26Corrigendum revises rights issue to 9,58,166 shares, ₹9,102.58 lakh issue size, ₹981.46 lakh GCP. ↗
- 7 Sep ’26Anondita Medicare says 9,58,000 rights shares need no odd-lot disposal; REs trade in lots of 10. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 |
|---|---|---|
| Sales | ▲ +80.4% | +53.7% |
| Operating profit | ▲ +93.8% | +63.2% |
| EPS | ▲ +37.0% | +47.3% |
| PAT | ▲ +110.0% | +61.5% |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +80.4%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
No score — no price data. The eight growth columns arrive with the quarter's Excel import; until then a number here would be invented.
How it compares with its rivals FMCG · 6 of 15 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Anondita Medi. | ₹1,107 | 63.0× | ₹2,108 Cr | 43.6% | +85.9% | +82.8% |
| Godrej Consumer | ₹882 | 43.5× | ₹90,204 Cr | 18.8% | +10.6% | +15.4% |
| Dabur India | ₹387 | 34.6× | ₹68,723 Cr | 20.3% | +15.0% | +10.6% |
| Colgate-Palmoliv | ₹1,876 | 37.3× | ₹51,029 Cr | 108.0% | +7.8% | +11.8% |
| Cupid | ₹278 | 272.5× | ₹37,442 Cr | 33.9% | +194.0% | +142.5% |
| P & G Hygiene | ₹7,682 | 31.5× | ₹24,935 Cr | 157.2% | −34.3% | −4.9% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Mar 2026
| Are the margins widening? | yes — widening, and steadily | operating margin 31% → 38% over 18 months |
|---|---|---|
| Did the profit turn into cash? | very little of it arrived as cash | 28% last year, -5% over three · free cash flow −₹52 cr, positive in 0 of 2 years |
| Is the growth borrowed? | lightly borrowed | ₹34 cr — 0.26× its own equity (was 0.71×) |
| Is it being collected? | collection is steady | 138 days to collect, up 11 in a year · cash cycle 215 days |
| Who has been buying? | promoter stake unchanged on record | promoters 62.4% · FIIs 3.4% · DIIs 5.7% |
| What does it earn on its capital? | earns a high return on the capital it employs | ROCE 43.6% · ROE 40.0% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
Against it
- Stock is trading at 16.5 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.